investig
mechan
glycyrrhizin
gl
main
activ
compon
licoric
root
protect
cell
infect
influenza
viru
iav
found
gl
treatment
lead
clear
reduct
number
iavinfect
human
lung
cell
well
reduct
titer
antivir
effect
howev
limit
one
two
viru
replic
cycl
analysi
differ
gl
treatment
protocol
suggest
antivir
effect
gl
limit
earli
step
viru
replic
cycl
direct
inhibitori
action
gl
iav
particl
could
exclud
gl
interact
viru
receptor
bind
either
antivir
effect
gl
abolish
treatment
h
viru
infect
wherea
pretreat
treatment
viru
adsorpt
led
reduct
cytopath
effect
reduc
viral
rna
within
cell
cell
supernat
reduc
viral
hemagglutin
titer
detail
viru
uptak
analys
unambigu
demonstr
reduc
viru
uptak
variou
gltreat
cell
observ
lead
conclus
antivir
activ
gl
mediat
interact
cell
membran
like
result
reduc
endocytot
activ
henc
reduc
viru
uptak
insight
might
help
design
structur
relat
compound
lead
potent
antiinfluenza
therapeut
viral
respiratori
infect
common
diseas
experienc
peopl
age
influenza
viru
iav
consid
major
human
pathogen
caus
million
case
sever
ill
normal
season
death
worldwid
pandem
outbreak
occur
result
high
mortal
rate
mainli
due
lack
preexist
immun
new
viru
strain
horimoto
kawaoka
current
two
class
usfdaapprov
antivir
drug
avail
treatment
prevent
influenza
adamantan
deriv
amantadin
rimantadin
neuraminidas
inhibitor
nai
zanamivir
oseltamivir
nicholson
et
al
target
type
drug
viral
protein
optimum
efficaci
must
administ
within
h
symptom
onset
adamantan
specif
influenza
viru
block
function
viral
ion
channel
protein
therebi
inhibit
viru
uncoat
upon
infect
davi
et
al
nai
block
enzymat
activ
viral
neuraminidas
na
prevent
releas
virion
bud
host
cell
colman
et
al
zanamivir
oseltamivir
current
prescrib
treatment
prophylaxi
influenza
stockpil
pandem
influenza
besid
two
major
group
antiinfluenza
drug
sever
approach
includ
inhibitor
viral
rna
transcript
small
interf
rna
inhibitor
viruscel
fusion
proteolyt
process
ha
exist
far
altern
drug
licens
lagoja
de
clercq
henc
need
market
new
antivir
drug
triterpen
glycosid
glycyrrhiz
acid
glycyrrhizin
gl
aglycon
acid
intens
investig
bioactiv
compound
licoric
root
glycyrrhiza
radix
baltina
compound
report
antitumor
antioxid
antiinflammatori
antivir
properti
shibata
et
al
mechan
gl
exert
variou
effect
still
remain
unclear
gl
activ
broad
spectrum
virus
includ
herp
corona
alpha
flavivirus
human
immunodefici
viru
vaccinia
polio
type
vesicular
stomat
viru
iav
briolant
et
al
cinatl
et
al
cranc
et
al
hoever
et
al
lampi
et
al
lin
pompei
et
al
pompei
et
al
sasaki
et
al
takei
et
al
utsunomiya
et
al
particularli
antiinfluenza
activ
gl
demonstr
embryon
hen
egg
mice
vivo
howev
detail
analysi
antivir
effect
underli
mechan
cell
cultur
report
far
earli
work
attribut
antivir
activ
gl
induct
ifngamma
abe
et
al
protect
mechan
action
describ
gltreat
mice
lethal
infect
iav
utsunomiya
et
al
howev
strong
evid
gl
exert
least
part
antivir
activ
directli
affect
hostviru
interact
rather
immun
modul
evalu
differ
gl
treatment
protocol
cell
infect
coronavirus
well
result
screen
experi
use
gl
deriv
anticoronaviru
activ
suggest
gl
interfer
viru
adsorpt
receptor
penetr
ie
earli
step
viru
reproduct
cycl
cinatl
et
al
hoever
et
al
moreov
inhibit
viru
penetr
propos
mechan
action
gl
epsteinbarr
viru
infect
lin
hypothesi
support
data
harada
demonstr
modifi
fluiditi
lipid
bilay
viral
plasma
membran
gl
treatment
lead
inhibit
fusion
pore
format
henc
reduc
infect
variou
virus
shown
detail
howev
verif
hypothesi
done
iav
studi
analyz
antiinfluenza
activ
gl
present
detail
inform
potenti
mode
action
gl
combat
influenza
viru
infect
effect
gl
iav
replic
demonstr
variou
endpoint
differ
cell
line
differ
gl
treatment
protocol
synchron
infect
appli
elucid
exact
phase
viral
reproduct
cycl
affect
gl
eventu
impact
gl
viru
uptak
analyz
use
fluorescencelabel
iav
human
endotheli
lung
cell
human
lung
fibroblast
cell
mardindarbi
canin
kidney
cell
mdck
obtain
american
tissu
cultur
collect
cell
cultiv
ham
medium
paa
contain
heatinactiv
fetal
bovin
serum
fb
paa
mm
lglutamin
paa
mdck
cell
cultiv
dmemham
medium
biochrom
ag
contain
heatinactiv
fb
mm
lglutamin
influenza
viru
obtain
american
tissu
cultur
collect
viru
stock
prepar
propag
viru
mdck
cell
respect
approxim
h
postinfect
cell
supernat
harvest
clarifi
centrifug
g
c
min
aliquot
store
c
infecti
viru
titer
determin
cell
cultur
infect
dose
analysi
correspond
cell
line
viru
propag
mdck
cell
calcul
method
reed
muench
fluoresc
label
iav
perform
establish
yoshimura
ohnishi
slight
modif
viru
amplifi
mdck
cell
supernat
harvest
cell
debri
remov
centrifug
g
c
min
viru
particl
purifi
centrifug
use
rotor
beckman
sucros
cushion
trisbuff
salin
tri
sodium
chlorid
ph
g
min
c
pellet
resuspend
overnight
pb
fifti
microlit
sodium
bicarbon
buffer
ad
l
viru
suspens
mgml
ad
alexa
fluor
protein
suspens
contain
magnet
stir
bar
alexa
fluor
protein
label
kit
invitrogen
incub
h
room
temperatur
pass
biorad
biogel
contain
column
remov
unconjug
dye
label
viru
elut
use
pb
filter
filter
remov
viru
aggreg
aliquot
fluorescencelabel
viru
store
c
titer
determin
method
cell
seed
h
prior
infect
growth
medium
reach
approxim
confluenc
infect
cell
wash
twice
pb
inocul
viru
dilut
optimem
invitrogen
dmemham
medium
h
room
temperatur
viru
inoculum
remov
cell
monolay
wash
pb
incub
c
co
infect
medium
optimem
gml
trypsin
antibiot
paa
p
optimem
antibiot
mdck
dmemham
gml
trypsin
antibiot
unless
state
otherwis
gl
ad
infect
medium
synchron
infect
cell
wash
ice
cold
pb
incub
ice
cold
optimem
dmemham
mdck
min
ice
medium
remov
precool
viru
inoculum
ad
incub
ice
h
inoculum
remov
cell
wash
pb
incub
infect
medium
c
co
five
millimolar
gl
stock
solut
prepar
correspond
infect
medium
ad
specifi
remov
surfaceassoci
viru
cell
treat
neuraminidas
type
v
clostridium
perfringen
purifi
use
nanlactos
sigma
matlin
et
al
remov
viru
inoculum
cell
wash
pb
medium
ad
uptak
bound
viru
allow
h
c
medium
remov
cell
wash
precool
pb
five
uml
neuraminidas
ad
incub
ice
min
shaker
eventu
cell
intens
wash
pb
lyse
viral
rna
analysi
cytotox
cytopath
effect
antivir
activ
estim
quantifi
number
viabl
cell
use
atpbas
celltitreglo
luminesc
cell
viabil
assay
promega
accord
manufactur
instruct
slight
modif
briefli
cell
cultur
supernat
remov
cell
lyse
l
l
celltitreglo
reagent
min
rt
lysat
transfer
white
opaquewal
multiwel
plate
corn
luminesc
measur
use
biotek
synergi
ht
plate
reader
gene
transcript
level
amount
viral
rna
cell
supernat
estim
use
quantigen
panom
gene
analysi
system
allow
quantif
rna
directli
cell
lysat
cell
cultur
supernat
without
requir
purif
revers
transcript
step
quantigen
hybrid
base
technolog
use
immobilis
probe
set
specif
gene
interest
specif
target
rna
sampl
upon
rna
hybrid
alkalin
phosphatas
conjug
label
probe
bind
lead
convers
chemiluminisc
substrat
gener
luminesc
linearli
proport
number
rna
molecul
present
sampl
sampl
analyz
accord
manufactur
protocol
cell
either
analyz
directli
store
c
cell
lysi
probe
set
design
gener
done
quantigen
human
gapdh
standard
probe
set
panom
cat
use
customis
probe
set
gener
canin
gapdh
genbank
access
influenza
viru
gene
segment
gene
genbank
access
viru
contain
cell
supernat
also
analyz
directli
store
c
analysi
cell
lysat
signal
gene
interest
normal
signal
deriv
housekeep
gene
gapdh
signal
obtain
viru
contain
cell
supernat
directli
proport
amount
viru
contain
sampl
standard
chicken
red
blood
cell
crbc
human
red
blood
cell
hrbc
solut
prepar
accord
manual
viru
contain
cell
cultur
supernat
serial
dilut
crbc
ad
equal
volum
min
incub
c
rbc
neg
well
sediment
form
red
button
wherea
posit
well
opaqu
appear
sediment
ha
titer
given
hemagglutin
l
l
mdck
cell
expos
fluorescencelabel
unlabel
viru
synchron
infect
viru
adsorpt
analysi
cell
incub
inoculum
ice
h
wash
chill
pb
harvest
scrape
suspend
intens
pipet
viru
uptak
analysi
cell
incub
medium
contain
gl
h
c
remov
inoculum
wash
pb
cell
harvest
trypsin
suspend
cell
fix
paraformaldehyd
wash
pb
analyz
viru
bind
uptak
use
fac
calibur
cell
quest
pro
softwar
bectondickinson
cell
fix
paraformaldehyd
pb
min
permeabil
triton
pb
min
block
goat
serum
plu
tween
pb
incub
iav
mous
antiinfluenza
nucleoprotein
np
monoclon
antibodi
chemicon
dilut
block
buffer
h
cell
incub
peroxidaselabel
antimous
antibodi
kpl
h
incub
min
precipitateform
peroxidas
substrat
true
blue
kpl
foci
count
visual
use
light
microscop
olympu
data
determin
least
biolog
triplic
gener
repres
least
two
separ
experi
result
depict
either
mean
standard
deviat
experi
n
singl
valu
experi
n
median
interquartil
rang
calcul
hemagglutin
titer
data
analyz
use
graphpad
prism
version
window
graphpad
softwar
san
diego
ca
statist
analysi
use
either
student
ttest
anova
bonferroni
posttest
compens
multipl
comparison
determin
effect
gl
infect
human
lung
cell
iav
cell
viabil
experi
demonstr
gl
induc
cytotox
mdck
cell
even
except
high
concentr
mm
medium
data
shown
thu
subsequ
vitro
studi
perform
gl
concentr
rang
mm
evalu
potenti
antivir
activ
gl
iav
untreat
cell
nonproduct
infect
without
trypsin
use
iav
multipl
infect
moi
infecti
viru
determin
per
number
cell
cultur
presenc
gl
ad
cell
cultur
remov
viru
inoculum
differ
time
point
postinfect
extent
infect
analyz
immun
stain
cell
iav
np
gl
treatment
lead
signific
reduct
number
infect
cell
fig
number
np
posit
cell
reduc
h
postinfect
p
respect
number
np
posit
cell
significantli
reduc
h
postinfect
p
indic
consider
antivir
activ
gl
concentr
next
untreat
cell
product
infect
trypsin
use
iav
moi
incub
without
gl
concentr
mm
ad
togeth
infect
medium
remov
viru
inoculum
wash
pb
differ
endpoint
determin
h
postinfect
time
depend
manner
cell
viabil
decreas
fig
h
cell
viabil
reduc
untreat
infect
cell
thereaft
signific
increas
viru
titer
observ
fig
gltreat
infect
cell
virtual
cpe
observ
h
postinfect
compar
cpe
untreat
infect
cell
h
cpe
gltreat
cell
amount
h
still
cell
viabl
demonstr
sig
nificantli
improv
cell
viabil
p
gltreat
compar
untreat
infect
cell
h
postinfect
fig
reduct
cpe
compar
nongltreat
infect
cell
like
due
reduc
viru
product
reflect
signific
reduct
titer
p
h
postinfect
fig
reduct
viru
titer
log
could
resolv
modif
procedur
dilut
seri
allow
titer
differ
less
log
clearli
distinguish
moreov
reduc
viru
product
also
reflect
reduc
hemagglutin
titer
h
postinfect
tabl
significantli
reduc
amount
viral
rna
supernat
h
p
h
p
postinfect
fig
compar
untreat
infect
cell
addit
viral
rna
determin
cell
lysat
normal
gapdh
mrna
fig
h
rel
amount
viral
rna
reduc
p
p
correct
multipl
comparison
h
viral
transcript
reduc
p
gltreat
cell
fig
interestingli
signific
reduct
infecti
viru
titer
observ
h
postinfect
could
detect
later
time
point
fig
wherea
differ
amount
viru
particl
produc
determin
ha
tabl
rna
fig
analysi
appar
h
respect
later
time
point
earli
antivir
effect
superimpos
infect
cycl
eventu
affect
cell
per
well
day
upon
viral
infect
sinc
viru
titer
reduct
evid
earli
time
point
test
whether
addit
pretreat
cell
gl
would
amplifi
observ
effect
viral
rna
determin
lysat
cell
normal
gapdh
mrna
supplementari
fig
h
postinfect
low
level
viru
rna
detect
differ
amount
viral
rna
pretreat
compar
treatment
upon
viral
infect
could
observ
howev
h
addit
gl
pretreat
result
signific
reduct
viru
rna
p
reduct
upon
gl
pretreat
also
reflect
amount
viral
rna
detect
cell
supernat
h
postinfect
supplementari
fig
account
possibl
gl
bound
inactiv
time
henc
readili
avail
anymor
exert
antivir
effect
gl
supplement
h
infect
viral
rna
analyz
cell
supernat
supplementari
addit
gl
result
decreas
viral
rna
supernat
compar
gl
treatment
upon
infect
data
shown
first
evalu
whether
gl
would
capabl
neutral
viru
hemagglutinin
result
inhibit
bind
viral
hemagglutinin
ha
receptor
sugar
chain
skehel
wiley
thu
viru
hrbc
respect
incub
pb
gl
mm
h
room
temperatur
ha
titer
determin
tabl
differ
gltreat
viru
gltreat
hrbc
pb
treatment
detect
ha
titer
lead
conclus
gl
inhibit
viru
bind
receptor
addit
inhibit
neuraminidas
activ
gl
evalu
use
adnacetylneuramin
acid
substrat
convers
assay
wetheral
et
al
effect
observ
either
data
shown
use
differ
gl
treatment
protocol
synchron
cell
infect
sought
elucid
exact
phase
viral
reproduct
cycl
affect
gl
differ
treatment
protocol
depict
fig
arrow
indic
presenc
drug
cell
viru
infect
respect
cell
viabil
fig
ha
titer
tabl
determin
h
postinfect
viru
transcript
supernat
fig
analyz
h
postinfect
compar
infect
without
synchron
fig
effect
observ
appear
delay
approxim
h
probabl
due
fact
cell
metabol
temporarili
shut
cool
synchron
h
postinfect
clear
differ
variou
treatment
protocol
observ
preincub
cell
gl
andor
viru
adsorpt
remov
thereaft
improv
cell
viabil
slightli
significantli
p
treatment
tabl
hemagglutin
titer
cell
supernat
iav
infect
differ
gl
mm
treatment
protocol
n
median
interquartil
rang
cell
viabil
viral
rna
cell
supernat
compar
untreat
p
p
p
one
valu
exclud
due
oper
error
b
respect
compar
untreat
cell
h
postinfect
fig
correspondingli
amount
viru
rna
cell
supernat
treatment
reduc
slightli
p
h
postinfect
disappear
h
notabl
signific
reduct
also
observ
treatment
b
fig
h
moreov
posit
effect
cell
viabil
result
gl
pretreat
also
evid
treatment
f
compar
e
fig
weak
effect
howev
appar
ha
titer
tabl
like
due
insuffici
resolv
power
assay
interestingli
gl
present
viru
adsorpt
treatment
c
effect
cell
viabil
fig
viral
rna
fig
ha
titer
tabl
compar
untreat
detect
result
correspond
data
pretreat
experi
present
show
slight
protect
effect
gl
cell
prime
supplementari
fig
b
infect
cell
cultur
presenc
gl
h
cell
viabil
significantli
improv
compar
untreat
cell
h
p
fig
treatment
df
moreov
gl
present
throughout
experi
treatment
f
virtual
differ
viabil
uninfect
cell
detect
compar
untreat
cell
h
viabil
cell
treatment
df
higher
p
fig
detect
amount
viral
rna
cell
supernat
correspond
well
cell
viabil
cell
supernat
treatment
df
viral
rna
detect
compar
untreat
cell
h
fig
p
h
amount
viru
rna
still
reduc
compar
untreat
p
result
also
reflect
ha
titer
tabl
experi
gl
ad
h
infect
strikingli
reduct
amount
viral
rna
h
postinfect
observ
supernat
late
treatment
compar
protocol
gl
ad
right
remov
viru
inoculum
fig
clearli
demonstr
gl
mainli
interfer
earli
stage
iav
reproduct
cycl
probabl
viru
uptak
via
endocytosi
fusion
viru
endosom
membran
uncoat
order
demonstr
gl
inde
reduc
amount
viru
particl
enter
cell
viral
rna
quantifi
immedi
viru
uptak
cell
pretreat
gl
gl
present
viru
adsorpt
uptak
achiev
maximum
antivir
effect
facilit
detect
mdck
cell
infect
moi
cell
lysat
analyz
h
incub
c
allow
viru
endocytosi
addit
discrimin
surfacebound
truli
intern
viru
cell
treat
neuraminidas
na
remov
receptorbound
yet
intern
virion
allow
viru
uptak
c
h
result
show
significantli
reduc
amount
viral
rna
gltreat
cell
compar
untreat
cell
p
fig
differ
also
reflect
natreat
cell
wherebi
overal
signal
somewhat
lower
compar
na
untreat
sampl
reduct
viral
rna
gltreat
cell
still
evid
clearli
demonstr
differ
caus
reduc
viru
bind
gl
treatment
inde
differ
amount
intern
viru
order
confirm
find
construct
fluorescencelabel
viru
analyz
impact
gl
viru
uptak
use
fac
mdck
cell
treat
mm
gl
respect
infect
fluorescencelabel
iav
differ
moi
analyz
possibl
differ
viru
adsorpt
gltreat
untreat
cell
fac
analysi
perform
immedi
remov
viru
inoculum
analyz
viru
uptak
cell
incub
h
c
allow
viru
endocytosi
prior
fac
analysi
reduct
approxim
label
viru
mdck
cell
detect
gltreat
cell
fig
show
fac
data
mdck
cell
infect
moi
fluorescencelabel
iav
compar
untreat
cell
almost
complet
inhibit
fluorescencelabel
viru
cell
entri
observ
demonstr
shift
cell
popul
toward
control
cell
popul
reduct
viru
uptak
independ
viru
load
use
tabl
howev
signific
differ
detect
gltreat
untreat
cell
analyz
directli
viru
adsorpt
tabl
result
confirm
effect
glbind
sole
viru
receptor
exclud
alreadi
shown
ha
assay
gltreat
hrbc
viru
tabl
influenza
one
common
diseas
caus
influenza
viru
infect
constitut
seriou
health
problem
caus
signific
morbid
mortal
impos
substanti
econom
cost
year
efficaci
current
drug
limit
improv
therapi
need
glycyrrhizin
gl
use
japan
year
treatment
viral
hepat
well
known
broad
activ
sever
virus
vitro
vivo
includ
iav
sever
studi
describ
antivir
activ
gl
iav
data
howev
remain
inconsist
earli
studi
antivir
activ
gl
investig
rather
unconvent
way
egg
treat
gl
viru
titer
reduct
assess
hemagglutin
pompei
et
al
recent
studi
effect
gl
lethal
iavinfect
mice
demonstr
ever
cell
cultur
activ
gl
found
utsunomiya
et
al
present
studi
demonstr
first
time
gl
treatment
human
lung
cell
infect
iav
lead
signific
titer
reduct
well
reduct
cpe
amount
viral
rna
cell
lysat
cell
cultur
supernat
fig
strikingli
even
high
concentr
mm
gl
fulli
block
viral
infect
host
cell
consequ
viral
replic
retard
clearli
display
earli
time
point
howev
time
day
depend
assay
setup
endpoint
measur
cell
affect
protect
effect
gl
eventu
vanish
question
moder
antivir
effect
observ
studi
consequ
gl
either
deplet
render
unavail
cell
experi
gl
could
possibl
bound
cultur
medium
constitu
suggest
ishida
et
al
ishida
et
al
studi
bind
gl
human
serum
serum
albumin
howev
replenish
gl
h
infect
significantli
enhanc
antivir
effect
data
shown
moreov
detail
hplc
analysi
gl
incub
differ
fb
contain
cell
cultur
media
follow
ultrafiltr
show
glbind
sera
compon
data
shown
use
differ
treatment
protocol
aim
identifi
precis
time
period
gl
exert
activ
viral
infect
cycl
data
clearli
show
gl
pretreat
slightli
improv
cell
viabil
reduc
viral
rna
cell
lysat
cell
cultur
supernat
fig
supplementari
fig
b
gl
present
viru
adsorpt
thereaft
antivir
effect
appreci
pronounc
divers
treatment
protocol
clearli
reveal
gl
reduc
viral
rna
cell
supernat
appli
h
infect
fig
result
lead
conclus
gl
interfer
earli
step
viral
reproduct
cycl
bind
viru
receptor
viru
uptak
endocytosi
uncoat
viru
within
cytoplasm
hypothesi
support
data
publish
epsteinbarr
viru
replic
author
claim
base
outcom
differ
gl
treatment
protocol
gl
affect
viru
penetr
howev
without
effect
viru
adsorpt
inactiv
lin
evalu
differ
gl
treatment
protocol
cell
infect
coronavirus
well
result
screen
experi
use
gl
deriv
anticoronaviru
activ
also
suggest
earli
step
viru
reproduct
cycl
respons
antivir
activ
gl
cinatl
et
al
hoever
et
al
iav
howev
pompei
et
al
suggest
late
step
viral
replic
cycl
affect
gl
wherea
other
even
unabl
detect
antivir
vitro
effect
gl
utsunomiya
et
al
latter
work
iav
protect
effect
observ
mous
model
sole
attribut
glinduc
secret
tcell
nevertheless
point
differ
viru
type
discuss
antivir
activ
gl
obvious
strongli
depend
natur
viru
experiment
setup
iav
howev
detail
studi
involv
gl
perform
far
elucid
antivir
mechan
action
base
variou
experiment
approach
data
strongli
suggest
gl
inhibit
cell
entri
rather
adsorpt
viru
clearli
show
gl
neither
block
viral
hemagglutinin
mask
viru
receptor
cell
surfac
tabl
differ
gltreat
untreat
cell
detect
viru
adsorpt
analyz
fac
tabl
moreov
remov
surfac
bound
virion
na
treatment
effect
gl
viral
penetr
compar
nauntreat
cell
fig
use
two
differ
approach
investig
effect
gl
viru
uptak
cell
could
clearli
demonstr
signific
reduct
viral
entri
upon
gl
treatment
depend
moi
use
viral
uptak
reduc
mdck
cell
cell
fac
analysi
reveal
proport
endocytos
viru
remain
virtual
constant
irrespect
viru
load
fulli
exclud
signal
detect
may
partial
result
viru
bound
cell
surfac
sinc
viral
rna
analysi
reveal
overal
signal
slightli
decreas
na
treatment
howev
contribut
cell
surfacebound
virion
overal
signal
found
minim
fig
reduct
fluiditi
plasma
membran
upon
gl
treatment
suggest
harada
studi
inhibit
viral
infect
gl
report
iav
human
immunodefici
shown
mostli
due
suppress
fluiditi
plasma
membran
viral
envelop
gl
incorpor
specif
author
postul
antivir
effect
due
inhibit
format
fusion
pore
howev
author
discrimin
two
differ
mode
uncoat
iav
viral
membran
directli
fuse
plasma
membran
viru
capsid
releas
cytoplasm
contrari
iav
taken
cell
endocytosi
viral
membran
eventu
fuse
endosom
membran
present
studi
clearli
demonstr
gl
imped
iav
uptak
suggest
harada
uncoat
influenza
viru
entri
nevertheless
process
cell
entri
endocytosi
iav
direct
fusion
viru
plasma
membran
depend
membran
fluiditi
like
alter
upon
gl
treatment
interestingli
nonenvelop
viru
type
polioviru
adenoviru
use
endocytosi
main
cellular
entri
pathway
antivir
activ
gl
far
describ
envelop
viru
type
interestingli
gl
report
inact
polioviru
infect
harada
author
use
method
dilut
seri
detect
viru
titer
reduct
experi
iav
would
necessari
use
modifi
method
narrow
dilut
seri
definit
exclud
antivir
effect
gl
nonenvelop
virus
thu
investig
need
definit
exclud
antivir
effect
gl
nonenvelop
virus
conclus
clearli
demonstr
antivir
effect
gl
variou
iav
infect
cell
includ
human
lung
epitheli
cell
human
lung
fibroblast
shown
gl
inhibit
viru
uptak
like
interf
cellular
membran
eventu
lead
reduct
endocytosi
henc
gl
term
virustat
virucid
agent
interestingli
despit
high
concentr
necessari
exhibit
antivir
activ
gl
treatment
result
cytotox
high
concentr
translat
potenti
vivo
efficaci
beyond
scope
studi
howev
case
inhibitori
mechan
gl
describ
also
predomin
basi
potenti
antiinfluenza
effect
vivo
preclinicalclin
develop
challeng
unless
synergist
pharmacolog
action
obtain
view
mechanist
data
present
studi
may
form
interest
basi
medicin
chemistri
program
base
molecular
structur
gl
aim
identifi
deriv
increas
antivir
activ
